Aflibercept biosimiliar (Jingze Biotechnology)

阿柏西普生物类似药（景泽生物）

Report date: 2025/08/04 14:46:11

Base Information

Drug NameAflibercept biosimiliar (Jingze Biotechnology)
Drug Alias Name重组人血管内皮生长因子受体-抗体融合蛋白（景泽生物）重组人血管内皮生长因子受体-抗体融合蛋白眼用注射液（景泽生物）JZB05JZB-05
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaRetinal Vein OcclusionMacular Degeneration +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesChengdu Zeyan Biotechnology Co LtdShanghai Jingze Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Jingze Biotechnology Co LtdChengdu Zeyan Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaRetinal Vein OcclusionMacular Degeneration +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A